



Note: Water guidance for this chemical was updated in May 2017. Please see <http://www.health.state.mn.us/divs/eh/risk/guidance/gw/table.html#pfos> Web Publication Date: 5/4/2009

Chemical Name: Perfluorooctane Sulfonate

Synonym: PFOS

CAS: 1763-23-1 (acid)

29081-56-9 (ammonium salt)

70225-14-8 (diethanolamine salt)

2795-39-3 (potassium salt)

29457-72-5 (lithium salt)

Serum concentrations appear to be the best dose-metric for extrapolating to humans. At the present time the information necessary to estimate less than chronic doses (i.e., acute, short-term or subchronic) that would result in a given serum concentration is not available. Additional uncertainty exists regarding toxicokinetics in early life. Therefore, acute, short-term and subchronic HRLs will not be derived at this time.

Acute Non-Cancer Health Risk Limit (nHRL_{acute}) = Not Derived (Insufficient Data)

Short-term Non-Cancer Health Risk Limit (nHRL_{short-term}) = Not Derived (Insufficient Data)

Subchronic Non-Cancer Health Risk Limit (nHRL_{subchronic}) = Not Derived (Insufficient Data)

Chronic Non-Cancer Health Risk Limit (nHRL_{chronic}) = 0.3 ug/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Chronic intake rate, L/kg/d})}$$

$$= \frac{(0.00008 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ ug/mg})}{(0.049^* \text{ L/kg-d})}$$

$$= 0.327 \text{ rounded to } \mathbf{0.3 \text{ ug/L}}$$

* Intake rate used corresponds to the time-weighted average 95th% intake rate over first 27 years of life. Twenty-seven years represents the estimated duration to achieve steady-state serum concentration, based on a half-life of 5.4 years.

Reference Dose: 0.00008 mg/kg-d (Cynomolgus monkeys)

Source of toxicity value: MDH

Point of Departure: 35 mg/L serum concentration (BMDL) (Thomford et al 2002 as cited by OECD 2002 and Seacat et al 2002)

Human Equivalent Dose Adjustment: 0.0025 mg/kg-d
 [Dose mg/kg-d = (Ln2/1971 day half-life_{human}) x 35 mg/L x 0.2 L/kg (Vd)]

Total uncertainty factor: 30

UF allocation: 3 interspecies extrapolation for potential differences in toxicodynamics and 10 intraspecies variability

Critical effect(s): decreased HDL cholesterol, decreased total T3, increased TSH

Co-critical effect(s): decreased body weight and body weight gain in offspring

Additivity endpoint(s): Development (body weight/weight gain), Hepatic (liver) system, Thyroid (E)

Secondary effect(s): changes in immune function, delayed development (e.g., body weight gain, eye opening), decreased adult body weight gain & loss of fat tissue, increased severity of liver effects (e.g., histological changes), disruption of estrus cycle, decreased sperm count & increased sperm deformities, decreased serum leptin levels, increased incidence of neoplasms (e.g., liver, thyroid, mammary gland), increased mortality (offspring and adults)

Cancer Health Risk Limit (cHRL) = Not Applicable

Volatile: No

Summary of changes since 1993/1994 HRL promulgation:

No 1993/94 HRL value exists for PFOS. The chronic HRL (0.3 ug/L) is the same as the Good-cause exception HRL (0.3 ug/L) adopted August 1, 2007.

Summary of toxicity testing for health effects identified in the Health Standards Statute:

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity
Tested?	Sec. Observations ¹	Yes	Yes	Yes	Yes
Effects?	Yes	Yes ²	Yes ³	Yes ⁴	Yes ⁵

Note: Even if testing for a specific health effect was not conducted for this chemical, information about that effect may be available from studies conducted for other purposes. Most chemicals have been subject to multiple studies in which researchers identify a dose where no effects were observed, and the lowest dose that caused one or more effects. A toxicity value based on the effect observed at the lowest dose across all available studies is considered protective of all other effects that occur at higher doses.

Comments on extent of testing or effects:

Note – comparisons based on HED LOAEL or HED BMDLs are associated with higher uncertainty than comparisons based on serum levels.

¹ Thyroid hormonal perturbations have been observed in laboratory animals at serum levels and human equivalent dose (HED) levels similar to the critical study point of departure (serum BMDL) and HED-LOAEL. Alterations in thyroid hormone levels have been identified as a critical effect.

² Short-term immunotoxicity studies have shown that PFOS exposure alters several immunologic parameters (suppression of SRBC-specific IgM production and T-cell proliferation, increased natural killer cell activity) at HED levels below the critical study HED LOAEL. The biological significance of these effects is not entirely clear. Further study is needed to determine whether PFOS poses potential health risks to humans as a result of alterations in immune function, however, the MDH will include immune system as a secondary effect at this time.

³ Lower body weight, decreased total T4 and free T4, and increased relative liver weight have been reported at serum levels similar to the critical study point of departure (serum BMDL). These effects have been identified at co-critical effects. At serum levels approximately 2-fold higher than the critical study point of departure additional developmental effects (decreased pup viability, developmental delays) are observed. These additional effects are listed as secondary effects.

⁴ Increased incidence of abortions was noted in female rabbits at serum levels ~ 2-fold higher than the critical study point of departure (serum BMDL), however, these were associated with significant loss in body weights. Disruption of estrus cycling in female rats has also been noted at serum levels ~ 2-fold higher than the critical study BMDL serum levels. A male reproductive study in rats reported decreases in sperm count and increases in sperm deformities at HED levels 3-fold higher than the critical study HED LOAEL. Disruption of estrus cycling and spermatozoal effects are listed among the secondary effects.

⁵ Increased norepinephrine concentrations in the paraventricular nucleus of the hypothalamus have been reported in female rats at serum levels ~2-fold higher than the critical study point of departure (serum BMDL). These effects have been noted as secondary effects.

Hypoactive responses to nicotine has been observed in neonatal mice acutely exposed to HED levels > 30-fold higher than the critical study HED LOAEL, however, these effects were not observed at levels 3-fold higher. Convulsions, severe rigidity and body trembling have been observed in Rhesus monkeys exposed to HED levels approximately 30-fold higher than the critical study HED LOAEL.

References:

Alexander B and M Grice. 2006. Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. Final Report submitted to the EPA docket AR-226-3677.

Alexander BH and GW Olsen. 2007. Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. *Ann Epidemiol* 17:471-478.

Apelberg BJ, FR Witter, JB Herbstman, AM Calafat, RU Halden, LL Needham, LR Goldman. 2007. Cord Serum Concentrations of Perfluorooctane Sulfonate (PFOS) and Perfluorooctanoate (PFOA) in Relation to Weight and Size at Birth. *Env Health Perspect* 115:1679-1676. (on-line) doi:10.1289/ehp.10334 (available at <http://dx.doi.org/>)

Andersen, ME, et. al., 2006 Pharmacokinetic Modeling of Saturable, Renal Resorption of Perfluoroalkylacids in Monkeys – Probing the Determinants of Long Plasma Half-Lives. *Toxicology* (online) doi:10.1016/j.tox.2006.08.004

Austin et al., Neuroendocrine Effects of Perfluorooctane Sulfonate in Rats. *Env Health Perspect* 111(12)1485-1489, 2003

Bondy G, I Curran, L Coady, C Armstrong, M Parenteau, V Liston, L Hierlihy, J Shenton. Immunomodulation by perfluorooctanesulfonate (PFOS) in a 28-day rat feeding study. *The Toxicologist*, Abstract #101, 2006.

Butenhoff et al, Perfluorooctane Sulfonate-Induced Perinatal Mortality in Rat Pups is Associated with a Steep Dose-Response. *The Toxicologist* 66(1): 25 (Abstract 120), 2002.

Butenhoff et al, Thyroid hormone status in adult female rats after an oral dose of perfluorooctanesulfonate (PFOS). *The Toxicologist*, Abstract #1740, 2005.

Calafat A, LY Wong, Z Kuklennyik, JA Reidy, and LL Needham. 2007. Polyfluoroalkyl Chemicals in the U.S. Population: Data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and Comparisons to NHANES 1999–2000. *Environmental Health Perspectives* 115:1596–1602

Chang, SC, JR Thibodeaux, ML Eastvold, DJ Ehresman, JA Bjork, JW Froehlick, CS Lau, RJ Singh, KB Wallace, JL Butenhoff. 2007a. Negative bias from analog methods used in the analysis of free thyroxine in rat serum containing perfluorooctanesulfonate (PFOS). *Toxicology* (advanced access doi.10.1016/j.tox.2007.01.020)

Chang SC, JA Hart, DJ Ehresman, JL Butenhoff. 2007b. Rat serum thyroid status during and after 28 daily oral doses of perfluorooctanesulfonate. Poster presentation at the International Congress of Toxicology XI Meeting, July 15-19, 2007. Montreal, Canada.

Cohen LH, EJ Pieterman, E Goegee-de Nobel. 2006. The effect of 3 perfluorinated alkyl sulphonated on cholesterol/bile acid metabolism in 15%-fat fed E3-Leiden transgenic mice in vivo and on fatty acid conversion into cholesterol in rat hepatocytes in vitro. Project/study number 031.10074/3M-02 Final Study Report December 4, 2006

Curran et al., Perfluorooctanesulfonate (PFOS) Toxicity in the Rat: A 28-Day Feeding Study. *The Toxicologist* Abstract #102, 2006

Ehresman, DJ, S Chang, JA Bjork, JA Hart, PH Lieder, KB Wallace, JL Butenhoff. 2007. Increased acyl CoA oxidase activity in rats after five consecutive daily doses of perfluorobutanesulfonate, perfluorohexanesulfonate, and perfluorooctanesulfonate. *The Toxicologist*, Abstract #865.

EPA 2003. Toxicological Review of Perfluorooctane Sulfonate (PFOS) In Support of Summary Information on the Integrated Risk Information System (IRIS). September 2003. External Peer Review Draft.

Fan YO, Jin YH, Ma YX, Zhang YH 2005. [Effects of perfluorooctane sulfonate on spermiogenesis function of male rats] [Article in Chinese] Wei Sheng Yan Jiu. Jan;34(1):37-9. (accessed at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15862018)

Food Standards Agency, Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. Second Draft Working Paper on the Tolerable Daily Intake for Perfluorooctane Sulfonate (May 2006).

Food Standards Agency (a United Kingdom Government Agency), Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. Minutes of the July 11, 2006 meeting.

Food Standards Agency, Committee on Toxicity (COT) of Chemicals in Food, Consumer Products and the Environment. COT Statement on the Tolerable Daily Intake for Perfluorooctane Sulfonate (November 2006). <http://www.food.gov.uk/multimedia/pdfs/cotstatementpfos200609.pdf>

Fromme H, M Schlummer, A Moller, L Gruber, G Wolz, J Ungewiss, S Bohmer, W Dekant, R Mayer, B Liebl, D Twardella. 2007. Exposure of an Adult Population to Perfluorinated Substances Using Duplicate Diet Portions and Biomonitoring Data. Environ Sci Technol 41:7928-7933.

Fuentes S, MT Colomina, J Rodriguez, P Vicens, JL Domingo. Interactions in developmental toxicology: concurrent exposure to perfluorooctane sulfonate (PFOS) and stress in pregnant mice. Toxicology Letters 164:81-89, 2006.

German Ministry of Health Drinking Water Commission. Provisional evaluation of PFT in drinking water with the guide substances perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) as examples. July 13,2006. <http://www.umweltbundesamt.de/uba-info-presse-e/hintergrund/pft-in-drinking-water.pdf>

Gordon, SC, S Schurch, M Amrein, M Schoel. 2007. Effects of perfluorinated acids on pulmonary surfactant properties in vitro. The Toxicologist, Abstract 437.

Grasty et al, Critical Period for Increased Neonatal Mortality Induced by Perfluorooctane Sulfonate (PFOS) in the Rat. The Toxicologist 66(1): 25 (Abstract 118), 2002.

Grasty et al., Perfluorooctane Sulfonate (PFOS) Alters Lung Development in the Neonatal Rat. The Toxicologist, Abstract # 1916, 2004.

Grice MM, BH Alexander, R Hoffbeck, DM Kampa. 2007. Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. J Occup Environ Med 49:722-729.

Harada K, K Inoue, A Morikawa, T Yoshinaga, N Saito, A Koizumi 2005. Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion. Environ Research 99:253-261.

Hu Wen yue, PD. Jones, W DeCoen, L King, P Fraker, J Newsted and JP Giesy 2003. Alterations in cell membrane properties caused by perfluorinated compounds. *Comparative Biochemistry & Physiology Part C* 135:77-88.

Hu Wen yue, PD. Jones, T Celius and JP Giesy 2005. Identification of genes responsive to PFOS using gene expression profiling. *Environmental Toxicology and Pharmacology Jan (Vol 19, Issue 1):* 57-70.

Inoue K, F Okada, R Ito, S Kato, S Sasaki, S Nakahima, A Uno, Y Saijo, F Sata, Y Yoshimura, R Kishi, H Nakazawa 2004. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. *Environmental Health Perspectives* 112:1204-1207.

Jernbro S, PS Rocha, S Keiter, D Skutlarek, H Farber, PD Jones, JP Geisy, H Hollert, M Engwall. 2007. Perfluorooctane sulfonate increases the genotoxicity of cyclophosphamide in the micronucleus assay with V79 cells. Further proof of alterations in cell membrane properties caused by PFOS. *Environ Sci Pollut Res Int* 14(2):85-87.

Johansson, N, et al., 2006. Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes deranged behaviour and increased susceptibility of the cholinergic system in adult mice. *The Toxicologist Abstract # 1458*

Johansson N, Fredriksson A, Eriksson P, 2007 Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes neurobehavioural defects in adult mice. Accepted manuscript. *Neurotoxicology* doi:10.1016/j.neuro.2007.10.008

Karrman A, I Ericson, B van Bavel, PO Darnerud, M Aune, A Glynn, S Lignell and G Lindstrom. 2007. Exposure of Perfluorinated Chemicals through Lactation – Levels of Matched Human Milk and Serum and a Temporal Trend, 1996 – 2004, in Sweden. *Environmental Health Perspectives* 115:226-230 (Online November 2006)

Keil DE, T Mehlman, L Butterworth, MM Peden-Adams. 2005 Gestational exposure to PFOS suppresses immunological function in F1 mice. *The Toxicologist Abstract #882, 2005.*

Keil D, J EuDaly, J Berger, J Pangallo, M Peden-Adams 2007. PFOS-induced immune modulation in B6C3F1 mice following oral exposure. *The Toxicologist, Abstract 309. 2007*

Lau, et al., 2003. Exposure to Perfluorooctane Sulfonate during Pregnancy in Rat and Mouse. II. Postnatal Evaluations. *Tox Sci* 74: 382-392.

Lau, et al., 2004. The developmental toxicity of perfluoroalkyl acids and their derivatives. *Tox Appl Pharm* 198:231-241.

Lau et al, 2006. Evaluation of Perfluorooctane Sulfonate (PFOS) in Rat Brain. *The Toxicologist Abstract #576.*

Lau et al, 2007. Perfluoroalkyl Acids: A Review of Monitoring and Toxicological Findings. *Tox Sci* 99:336-394.

Lieder PH, PE Noker, GS Gorman, SC Tanaka, JL Butenhoff. 2006. Elimination Pharmacokinetics of a Series of Perfluorinated Alkyl Carboxylate and Sulfonates (C4, C6 and C8) in Male and Female Cynomolgus Monkeys. Poster presentation at the 2006 European SETAC meeting in Den Hague, Netherlands.

Logan MN, JR Thibodeaux, RG Hanson, M Strynar, A Lindstrom, C Lau. 2004. Effects of perfluorooctane sulfonate (PFOS) on thyroid hormone status in adult and neonatal rats. *The Toxicologist Abstract #1917*

Luebker, D. et al., Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. *Toxicology* 215:126-148, 2005a.

Luebker, D. et al., Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: Dose-response, and biochemical and pharmacokinetic parameters. *Toxicology* 215:149-169, 2005b.

Maras, M et al., 2006. Estrogen-like properties of fluorotelomer alcohols as revealed by MCF-7 breast cancer cell proliferation. *Env Hlth Perspec* 114(1):100-105.

Martin MT, RJ Brennan, W Hu, E Ayanoglu, C Lau, H Ren, CR Wood, JC Corton, RJ Kavlock, DJ Dix. 2007. Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity. *Tox Sci* 97(2):595-613, 2007.

Matsubara, K, T Nakahari, H Yoshida, T Kuroiwa, KH Harada, K Inoue, A Koizumi. 2007. Effect of perfluorooctane sulfonate on tracheal ciliary beating frequency in mice. *Toxicology* 236:190-198.

Midasch, O, T Schettgen, J Angerer. 2006. Pilot Study on the perfluorooctanesulfonate and perfluorooctanoate exposure on the German population. *Int J Hyg Env Hlth* 209:489-496.

Midasch, O, H Drexler, N Hart, MW Beckmann, J Angerer. 2007. Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. *Int Arch Occup Env Hlth* 80:643-648.

MPCA 2007. Surface Water Quality Criterion for Perfluorooctane Sulfonic Acid. STS Project 200604796. <http://www.pca.state.mn.us/publications/pfos-report.pdf>

Olsen et al. 2003a. An Occupational Exposure Assessment of a Perfluorooctanesulfonyl Fluoride Production Site: Biomonitoring. *AIHA Journal* 64:651-659.

Olsen et al, 2003b. Epidemiologic Assessment of Worker Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Concentrations and Medical Surveillance Examinations. *J Occup Environ Med* 45:260-270.

Olsen et al, 2005 Evaluation of the half-life (t_{1/2}) of elimination of perfluorooctanesulfonate (PFOS), perfluorohexanesulfonate (PFHS) and perfluorooctanoate (PFOA) from human serum. FLUOROS:

International Symposium on Fluorinated Alky Organics in the Environment, TOX017)

Olsen GW, JM Burris, DJ Ehresman, JW Froehlich, AM Seacat, JL Butenhoff, LR Zobel. 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. *Environmental Health Perspectives* 115:1298-1305.

Organization for Economic Co-operation and Development (OECD) Nov. 21, 2002. Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and Its Salts.

http://www.oecd.org/document/58/0,2340,en_2649_37465_2384378_1_1_1_37465,00.html#3

(Accessed Nov. 2002)

Peden-Adams, et al., Oral Exposure to PFOS for 28 Days Suppresses Immunological Function in B6C3F1 Mice. *The Toxicologist Abstract #573*, 2006.

Peden-Adams, MM, JG EuDaly, S Dabra, A EuDaly, L Heesemann, J Smythe, DE Keil. 2007 Suppression of Humoral Immunity Following Exposure to the Perfluorinated Insecticide Sulfluramid. *J Tox Env Health Part A* 70:1130-1141

Savitz DA. 2007. Guest Editorial. Biomarkers of perfluorinated chemicals and birth weight. *Environmental Health Perspectives* 115:A528-529.

Seacat et al., Subchronic Toxicity Studies on Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys. *Tox Sci* 68:249-264, 2002

Takacs ML and BD Abbot. 2007. Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors (α , β/δ , γ) by Perfluorooctanoic Acid and Perfluorooctane Sulfonate *Toxicological Sciences* 95(1), 108-117.

Tan, Y, H Clewell, J Butenhoff, G Olsen, M Anderson. 2007. Physiologically-motivated pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacides in monkeys and rats. *The Toxicologist, Supplement to Toxicological Sciences*. Abstract 386.

Tanaka et al., 2005. Thyroid hormone status in adult rats given oral doses of perfluorooctanesulfonate. *FLUOROS: International Symposium on Fluorinated Alky Organics in the Environment, TOX018)*

Tanaka, S, et al. 2006 Effects of Perfluorooctanesulfonate on ^{125}I Elimination in Rats after a Single Intravenous Dose of ^{125}I -Labeled Thyroxine. *The Toxicologist Abstract #573*

Tao L, H Spliethoff, K Kannan. 2006 Biomonitoring of perfluorochemical exposure in newborn infants from New York State using blood spots: 1997 to 2004. SETAC (Society of Environmental Toxicology and Chemistry) North America 27th Annual Meeting, Montreal, Canada.

Thayer, K. 2002. Environmental Working Group: Perfluorinated chemicals: Justification for inclusion of this chemical class in the national report on human exposure to environmental chemicals.

http://www.ewg.org/reports/pfcworld/pdf/EWG_CDC.pdf

Thibodeaux, et al., Exposure to Perfluorooctane Sulfonate during Pregnancy in Rat and Mouse. I. Maternal and Prenatal Evaluations. *Tox Sci* 74: 369-381, 2003.

Thomford, P. 2002 Final Report: 104 Week Dietary Chronic Toxicity and Carcinogenicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS: T-6295) in Rats. (Abstract only).

Tittlemier SA, K Pepper, C Seymour, J Moisey, R Bronson, XL Cao, RW Dabeka. 2007. Dietary Exposure of Canadians to Perfluorinated Carboxylates and Perfluorooctane Sulfonate via Consumption of Meat, Fish, Fast Foods, and Food Items Prepared in Their Packaging. *J Agric Food Chem* 55:3202-3210.

3M 2002. Personal communication from Dr. John Butenhoff. Nov 25, 2002. Benchmark doses from the 6-month oral dosing study in monkeys developed by Dr. Gaylor.

3M 2003. Environmental and Health Assessment of Perfluorooctane Sulfonic Acid and Its Salts.

United Kingdom Environmental Agency 2004. Environmental Risk Evaluation Report: Perfluorooctanesulphonate (PFOS).

United Kingdom, Drinking Water Inspectorate 2007. Guidance on the water supply (water quality) regulations 2000/2001 specific to PFOS (perfluorooctane sulphonate) and PFOA (perfluooctanoic acid) concentrations in drinking water.

Vyas SM, I Kania-Korwel, HJ Lehmler. 2007. Differences in isomer composition of perfluorooctanesulfonyl (PFOS) derivatives. *J Env Sci Health, Part A* 42:249-255.